Vaccine Programs:

Dengue

A balanced, tetravalent Dengue vaccine based on contemporary strains of Dengue

There are no available treatments or safe vaccines against Dengue available for adults. Current vaccines against Dengue are based on old viral strains from the 1970s or 1980s. Using our synthetic biology-based approach, Codagenix designed a balanced, tetravalent Dengue vaccine based on contemporary strains of dengue. The Codagenix Dengue vaccine is designed to protect both civilians and deploying troops against all four Dengue serotypes, without causing enhanced disease. In preclinical studies, the vaccine is able to protect animals against Dengue virus after just one dose.

Global Need

50 Million

Dengue cases worldwide
(WHO estimate)

40%

Of global population live
In areas with risk of dengue

1,176,529

Cases in the Americas
(2014)

There are four serotypes of Dengue virus. Sequential infection with multiple serotypes can lead to life-threatening disease through antibody-dependent enhancement (ADE). Current vaccines cannot prevent ADE and thus contribute to severe disease following infection with multiple serotypes. The Codagenix approach to vaccine development allows us to rationally balance the attenuation of multiple vaccine strains such that all four serotypes stimulate neutralizing antibodies at a similar level. This balancing prevents ADE and allows for equal protection against all four Dengue serotypes without risk of severe disease.

Patient resources